Paras Biopharmaceuticals Finland Oy is an up-and-coming biopharmaceutical technology development company which has successfully developed the Diabrid Platform Technology proprietary for the high level expression of biosimilars in specially designed genetically stable clones.

Paras Biopharmaceuticals Finland Oy is a joint venture started in 2012 by a team of scientists and technologists who have extensive research experience and skills in the development of biologics and biosimilar technologies. Paras Biopharmaceuticals Finland Oy engages in the development and improvement of biological processes and expression of recombinant proteins in E. Coli, Saccharomyces, and Pichia pastoris.

Technology & Products

Paras Biopharmaceuticals Finland Oy brings together the experience, skill and knowledge combined with its product and process development capabilities to create solution that enables value creation and provides unmatched advantages for the advancement of an offering in the healthcare sector. As a result, Paras Biopharmaceuticals Finland Oy has successfully developed an innovative platform, Diabrid Technology, which can be offered directly to biosimilar technologies within biologic API's for scale-up production in the following categories:

At Paras Biopharmaceuticals Finland Oy, we combine scientific excellence with unique infrastructure capabilities to generate innovative ways to simplify product and process development. We understand that the quality of the product and serving the market in time are the most important deliverables. We generate value from innovative ideas based on scientific and technological excellence allowing us to present innovative work from Finland.

Paras Biopharmaceuticals Finland Oy has a dedicated and highly specialized scientific and technology team who strives to bring new paradigms in biopharma technology to solve critical bioprocess issues in the most economical and effective manner while maintaining and improving product quality.

Paras Biopharmaceuticals Finland Oy is one of the most valued technology provider of therapeutic peptides and biosimilars focusing on recombinant proteins and therapeutic peptides produced by microbial expression systems.

Located at the heart of Nordic excellence, we have developed a strong network of the most prestigious academic and technological institutions in Finland. Based on years of background work, we bring to the market various innovative technologies for biopharmaceutical manufacturing to cater for our customer's medical needs.